$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Method of manufacturing solid dispersion 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-009/10
  • A61K-009/14
출원번호 US-0129133 (1993-11-15)
우선권정보 JP-0112554 (1991-04-16)
국제출원번호 PCT/JP92/00470 (1993-12-23)
§371/§102 date 19931115 (19931115)
국제공개번호 WO-9218106 (1992-10-29)
발명자 / 주소
  • Nakamichi Kouichi (Shiga JPX) Izumi Shogo (Kyoto JPX) Yasuura Hiroyuki (Shiga JPX)
출원인 / 주소
  • Nippon Shinyaku Company, Limited (JPX 03)
인용정보 피인용 횟수 : 203  인용 특허 : 0

초록

The object of this invention is to provide a process for producing a solid dispersion, which has overcome the disadvantages of the conventional production technology for solid dispersions. The invention comprises employing a twin-screw extruder in the production of a solid dispersion. In accordance

대표청구항

A process for producing a solid dispersion of a drug dissolved or dispersed in a polymer carrier or diluent which comprises passing a mixture comprising said drug and said polymer through a twin screw compounding extruder having retaining barrels, with said twin screw compounding extruder being equi

이 특허를 인용한 특허 (203)

  1. Boruah, Anima; Alikunju, Shanavas, 5-benzylaminomethyl-6-aminopyrazolo [3, 4 -B] pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis.
  2. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment.
  3. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment.
  4. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment.
  5. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment.
  6. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and anti-inflammation methods.
  7. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and anti-inflammation methods.
  8. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and anti-inflammation methods.
  9. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and anti-inflammation methods.
  10. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition.
  11. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition.
  12. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition.
  13. Tseng, Scheffer; He, Hua; Li, Wei, Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition.
  14. Njar, Vincent C. O.; Gediya, Lalji K.; Purushottamachar, Puranik; Godbole, Abhijit; Kwegyir-Afful, Andrew; Vasaitis, Tadas, Androgen receptor down-regulating agents and uses thereof.
  15. Njar, Vincent C. O.; Gediya, Lalji K.; Purushottamachar, Puranik; Godbole, Abhijit; Kwegyir-Afful, Andrew; Vasaitis, Tadas, Androgen receptor down-regulating agents and uses thereof.
  16. Baert, Lieven E. C.; Verreck, Geert; Thone, Dany, Antifungal compositions with improved bioavailability.
  17. Baert, Lieven Elvire Colette; Verreck, Geert; Thone, Dany, Antifungal compositions with improved bioavailability.
  18. Baert, Lieven Elvire Colette; Verreck, Geert; Thoné, Dany, Antifungal compositions with improved bioavailability.
  19. Baert,Lieven Elvire Colette; Verreck,Geert; Thon챕,Dany, Antifungal compositions with improved bioavailability.
  20. Curatolo, William J.; Nightingale, James A. S.; Shanker, Ravi M.; Sutton, Steven C., Basic drug compositions with enhanced bioavailability.
  21. Baruah, Anima; De, Dibyendu; Khanna, Ish Kumar; Pillarisetti, Sivaram; Maitra, Santanu; Alexander, Christopher W.; Sreenu, Jennepalli; Dager, Indu; Alikunju, Shanavas, Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors.
  22. Rachel S. Kohn ; Stephen J. Hanley ; Stephen J. Comiskey, Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same.
  23. Njar, Vincent C. O.; Zoubeidi, Amina; Ferrante, Karen; Corey, Eva; Jacoby, Douglas, Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies.
  24. Njar, Vincent C. O.; Zoubeidi, Amina; Ferrante, Karen; Corey, Eva; Jacoby, Douglas B., Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies.
  25. Brodie, Angela; Njar, Vincent C. O., C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity.
  26. Temtsin Krayz, Galia; Averbuch, Maryana; Zelkind, Ilya; Gitis, Larisa, Compositions comprising lipophilic active compounds and method for their preparation.
  27. Tseng, Scheffer; He, Hua, Compositions containing HC-HA complex and methods of use thereof.
  28. Tseng, Scheffer; He, Hua; Tighe, Sean; Zhang, Suzhen; Zhu, Ying-Tieng, Compositions containing HC-HA/PTX3 complexes and methods of use thereof.
  29. Tseng, Scheffer; He, Hua; Tighe, Sean; Zhang, Suzhen; Zhu, Ying-Tieng, Compositions containing HC-HA/PTX3 complexes and methods of use thereof.
  30. McWherter, Charles A.; Martin, Robert Louis; Karpf, David B.; Roberts, Brian K.; Lorenz, Douglas Alan; Ketner, Rodney James, Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine.
  31. McWherter, Charles A.; Martin, Robert Louis; Karpf, David B.; Roberts, Brian K.; Lorenz, Douglas Alan; Ketner, Rodney James, Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine.
  32. Tseng, Scheffer; Chua, Lorraine, Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof.
  33. Simon, Julian; Johnson, Graham; Rubel, Edwin; Raible, David; Gonzalez, Mario D.; Meltzer, Peter C.; Miao, Weishi, Compounds and methods for preventing or treating sensory hair cell death.
  34. Simon, Julian; Johnson, Graham; Rubel, Edwin; Chowdhury, Sarwat; Herr, R. Jason; Jiang, Qin; Chen, Xinchao; Owens, Kelly N.; Raible, David, Compounds and methods for preventing, treating and/or protecting against sensory hair cell death.
  35. Simon, Julian; Johnson, Graham; Rubel, Edwin; Chowdhury, Sarwat; Herr, R. Jason; Jiang, Qin; Chen, Xinchao; Owens, Kelly N; Raible, David, Compounds and methods for preventing, treating and/or protecting against sensory hair cell death.
  36. Cao, Jianguo; Wang, Zhijun; Grey, Jonathan; Rogers, Evan; Whitten, Jeffrey P., Compounds that modulate intracellular calcium.
  37. Rogers, Evan; Cao, Jianguo; Wang, Zhijun; Grey, Jonathan; Whitten, Jeffrey P., Compounds that modulate intracellular calcium.
  38. Appel, Leah E.; Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S.; Thombre, Avinash G., Controlled release by extrusion of solid amorphous dispersions of drugs.
  39. Appel, Leah E.; Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S.; Thombre, Avinash G., Controlled release by extrusion of solid amorphous dispersions of drugs.
  40. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  41. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  42. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  43. Oshlack, Benjamin; Huang, Hua Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  44. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  45. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  46. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  47. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  48. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  49. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  50. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  51. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  52. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  53. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  54. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  55. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  56. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  57. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  58. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  59. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  60. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K; Tonelli, Alfred, Controlled release hydrocodone formulations.
  61. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Controlled release hydrocodone formulations.
  62. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Controlled release hydrocodone formulations.
  63. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  64. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  65. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  66. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  67. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  68. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  69. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  70. Oshlack, Benjamin; Masselink, John K.; Huang, Hua-Pin; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  71. Oshlack Benjamin ; Chasin Mark ; Huang Hua-Pin, Extruded multi-particulates.
  72. Oshlack Benjamin ; Chasin Mark ; Huang Hua-Pin, Extruded orally administrable opioid formulations.
  73. Pourdeyhimi,Behnam; Holmes,Rory; Little,Trevor J., Fiber-based nano drug delivery systems (NDDS).
  74. Kumar, Ravi Seshagirirao, Formulations and methods for treatment of metabolic syndrome.
  75. Chen, Xin; Cheng, Peng; Clemens, L. Edward; Johnson, Jeffrey D.; Ma, Jingyuan; Murphy, Alison; Nashashibi, Imad; Rabbat, Christoper J.; Song, Jiangao; Wilson, Maria E.; Zhu, Yan; Zhao, Zuchun, Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders.
  76. Chen, Xin; Cheng, Peng; Clemens, L. Edward; Johnson, Jeffrey D.; Ma, Jingyuan; Murphy, Alison; Nashashibi, Imad; Rabbat, Christopher J.; Song, Jiangao; Wilson, Maria E.; Zhu, Yan; Zhao, Zuchun, Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders.
  77. Chen, Xin; Cheng, Peng; Clemens, L. Edward; Johnson, Jeffrey D.; Ma, Jingyuan; Murphy, Alison; Nashashibi, Imad; Rabbat, Christopher J.; Song, Jiangao; Wilson, Maria E.; Zhu, Yan; Zhao, Zuchun, Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders.
  78. Chen, Xin; Cheng, Peng; Clemens, L. Edward; Johnson, Jeffrey D.; Ma, Jingyuan; Murphy, Alison; Nashashibi, Imad; Rabbat, Christopher J.; Song, Jiangao; Wilson, Maria E.; Zhu, Yan; Zhao, Zuchun, Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders.
  79. Chen, Xin; Cheng, Peng; Clemens, L. Edward; Johnson, Jeffrey D.; Ma, Jingyuan; Murphy, Alison; Nashashibi, Imad; Rabbat, Christopher J.; Song, Jiangao; Wilson, Maria E.; Zhu, Yan; Zhao, Zuchun, Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders.
  80. Frisbee Steven E. ; Barrow Deirdre M. ; Cascone Joseph ; McCarthy Barry D. ; Kiernan Bernard M. ; Anwar Hanan S., Immediate release dosage forms containing microspheres.
  81. Beaton, Graham; Tucci, Fabio; Ravula, Satheesh B.; Wang, Hua-Yu, Inhibition of OLIG2 activity.
  82. Fort, James J.; Krill, Steven L.; Law, Devalina; Qiu, Yihong; Schmitt, Eric A., Inhibitors of crystallization in a solid dispersion.
  83. Gerhart, William; Keller, Manfred; Tutuncu, Ahmet; Soni, Pravin, Mast cell stabilizers treatment for systemic disorders.
  84. Gerhart, William; Keller, Manfred; Tutuncu, Ahmet; Soni, Pravin, Mast cell stabilizers treatment for systemic disorders.
  85. Gerhart, William; Keller, Manfred; Tutuncu, Ahmet; Soni, Pravin, Mast cell stabilizers treatment for systemic disorders.
  86. Gerhart, William; Keller, Manfred; Tutuncu, Ahmet; Soni, Pravin, Mast cell stabilizers treatment for systemic disorders.
  87. Oshlack Benjamin ; Chasin Mark ; Huang Hua-Pin ; Sackler David, Melt-extruded orally administrable opioid formulations.
  88. Oshlack, Benjamin; Chasin, Mark; Huang, Hua-Pin; Sackler, David, Melt-extruded orally administrable opioid formulations.
  89. Benjamin Oshlack ; Hua-Pin Huang ; Mark Chasin, Melt-extrusion multiparticulates.
  90. Oshlack, Benjamin; Chasin, Mark; Huang, Hua-Pin, Melt-extrusion multiparticulates.
  91. Oshlack,Benjamin; Chasin,Mark; Huang,Hua Pin, Melt-extrusion multiparticulates.
  92. Beyerinck, Ronald A.; Deibele, Heather L. M.; Dobry, Dan E.; Ray, Roderick J.; Settell, Dana M.; Spence, Ken R., Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus.
  93. Beyerinck, Ronald A.; Diebele, Heather L. M.; Dobry, Dan E.; Ray, Roderick J.; Settell, Dana M.; Spence, Ken R., Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus.
  94. Rein, Hubert; Steffens, Klaus-Jurgen, Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix.
  95. Yamada, Yasushi, Method for producing polyphenol composition.
  96. Walsh Leo, Method of producing a vitamin product.
  97. Sackler Richard ; Kaiko Robert ; Goldenheim Paul, Method of treating humans with opioid formulations having extended controlled release.
  98. Sackler, Richard; Kaiko, Robert; Goldenheim, Paul, Method of treating humans with opioid formulations having extended controlled release.
  99. Brunner, Philip; Tapsak, Mark; Janse, Michael, Methods for increasing throughput rates of solid-state extrusion devices.
  100. Gerhart, William; Soni, Pravin; Tutuncu, Ahmet, Methods for the treatment of mast cell related disorders with mast cell stabilizers.
  101. Gerhart, William; Keller, Manfred; Tutuncu, Ahmet; Soni, Pravin, Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders.
  102. Darcy, Trevor John; Gilbert, Steven Ray; Gordon, Gregory Charles; Chhabra, Rajeev; Allen, Jr., William Maxwell, Methods of delivering a health care active by administering personal health care articles comprising a filmament.
  103. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Methods of manufacturing oral dosage forms.
  104. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K; Tonelli, Alfred, Methods of manufacturing oral formulations.
  105. Tseng, Scheffer; Tan, Ek Kia; He, Hua, Methods of modulating bone remodeling.
  106. Tseng, Scheffer; Tan, Ek Kia; He, Hua, Methods of modulating bone remodeling.
  107. Tseng, Scheffer; Tan, Ek Kia; Chua, Lorraine, Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof.
  108. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K; Tonelli, Alfred, Methods of providing analgesia.
  109. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Methods of providing analgesia.
  110. Kanikanti, Venkata-Rangarao; Rupp, Roland; Brendel, Erich; Weisemann, Claus; Chantraine, Ernst, Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same.
  111. Ma, Jingyuan; Rabbat, Christopher J.; Song, Jiangao; Chen, Xin; Nashashibi, Imad; Zhao, Zuchun; Novack, Aaron; Shi, Dong Fang; Cheng, Peng; Zhu, Yan; Murphy, Alison, N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders.
  112. Ma, Jingyuan; Rabbat, Christopher J.; Song, Jiangao; Chen, Xin; Nashashibi, Imad; Zhao, Zuchun; Novack, Aaron; Shi, Dong Fang; Cheng, Peng; Zhu, Yan; Murphy, Alison, N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders.
  113. Bloom, Corey Jay; Crew, Marshall David; Smithey, Daniel Tod; Miller, Warren Kenyon; Morgen, Michael Mark, Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer.
  114. Miller, Warren Kenyon; Morgen, Michael Mark; Smithey, Daniel Tod, Nanoparticles comprising a drug, ethylcellulose, and a bile salt.
  115. Bloom, Corey Jay; Crew, Marshall David; Miller, Warren Kenyon; Morgen, Michael Mark; Smithey, Daniel Tod, Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer.
  116. Bloom, Corey J.; Crew, Marshall David; Miller, Warren Kenyon, Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer.
  117. Miller, Warren Kenyon, Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate.
  118. Oshlack, Benjamin; Wright, Curtis; Prater, Derek, Once-A day oxycodone formulations.
  119. Oshlack, Benjamin; Wright, Curtis; Prater, Derek, Once-a-day oxycodone formulations.
  120. Oshlack, Benjamin; Wright, Curtis; Prater, Derek, Once-a-day oxycodone formulations.
  121. Wimmer, Walter; Brogmann, Bianca; Hahn, Udo; Spitzley, Christof, Opioid analgesic.
  122. Chasin Mark ; Oshlack Benjamin ; Pedi ; Jr. Frank, Opioid formulations having extended controlled release.
  123. Chasin Mark ; Oshlack Benjamin ; Pedi ; Jr. Frank, Opioid formulations having extended controlled released.
  124. Baheti, Ankit; Padhi, Bijay Kumar; Vakada, Supritha; Raghuvanshi, Rajeev Singh, Oral composition of celecoxib for treatment of pain.
  125. Baheti, Ankit; Padhi, Bijay Kumar; Vakada, Supritha; Raghuvanshi, Rajeev Singh, Oral composition of celecoxib for treatment of pain.
  126. Oshlack Benjamin ; Chasin Mark, Orally administrable opioid formulations having extended duration of effect.
  127. Oshlack Benjamin ; Chasin Mark, Orally administrable opioid formulations having extended duration of effect.
  128. Oshlack, Benjamin; Chasin, Mark, Orally administrable opioid formulations having extended duration of effect.
  129. Oshlack,Benjamin; Chasin,Mark, Orally administrable opioid formulations having extended duration of effect.
  130. Oshlack, Benjamin; Wright, Curtis; Prater, Derek, Oxycodone formulations.
  131. Leslie Stewart Thomas,GBX ; Knott Trevor John,GBX ; Mohammad Hasssan,GBX ; Prater Derek Allan,GBX, Pharmaceutical composition containing a fusible carrier and method for producing the same.
  132. Watanabe, Shunsuke; Takemura, Shigeo; Tsutsui, Yuuki; Kondo, Himoru; Nakanishi, Kiyo; Sako, Kazuhiro; Sawada, Toyohiro, Pharmaceutical composition for oral use with improved absorption.
  133. Watanabe,Shunsuke; Takemura,Shigeo; Tsutsui,Yuuki; Kondo,Hiromu; Nakanishi,Kiyo; Sako,Kazuhiro; Sawada,Toyohiro, Pharmaceutical composition for oral use with improved absorption.
  134. Guitard Patrice,FRX ; Haeberlin Barbara,CHX ; Link Rainer,DEX ; Richter Friedrich,DEX, Pharmaceutical compositions.
  135. Guitard, Patrice; Haeberlin, Barbara; Link, Rainer; Richter, Friedrich, Pharmaceutical compositions.
  136. Guitard, Patrice; Haeberlin, Barbara; Link, Rainer; Richter, Friedrich, Pharmaceutical compositions comprising 33-epi-chloro-33-desoxy-ascomycin solid dispersions.
  137. Curatolo, William J.; Friesen, Dwayne T., Pharmaceutical compositions comprising drug and concentration-enhancing polymers.
  138. Miller, Warren Kenyon; Smithey, Daniel; Frankamp, Benjamin Lee; Tadday, Ralph, Pharmaceutical compositions comprising nanoparticles and a resuspending material.
  139. Guitard Patrice,FRX ; Haeberlin Barbara,CHX ; Link Rainer,DEX ; Richter Friedrich,DEX, Pharmaceutical compositions comprising rafamycin coprecipitates.
  140. Curatolo, William J.; Friesen, Dwayne T.; Gumkowski, Michael J.; Lorenz, Douglas A.; Nightingale, James A. S.; Ruggeri, Roger B.; Shanker, Ravi M., Pharmaceutical compositions of cholesteryl ester transfer protein inhibitor.
  141. Crew, Marshall D.; Curatolo, William J.; Friesen, Dwayne T.; Gumkowski, Michael J.; Lorenz, Douglas A.; Nightingale, James A. S.; Ruggeri, Roger B.; Shanker, Ravi M., Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors.
  142. Crew, Marshall D.; Curatolo, William J.; Friesen, Dwayne T.; Gumkowski, Michael Jon; Lorenz, Douglas A.; Nightingale, James A. S.; Ruggeri, Roger B.; Shanker, Ravi M., Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors.
  143. Crew,Marshall D.; Curatolo,William J.; Friesen,Dwayne T.; Gumkowski,Michael Jon; Lorenz,Douglas A.; Nightingale,James A. S.; Ruggeri,Roger B.; Shanker,Ravi M., Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors.
  144. Curatolo,William J.; Friesen,Dwayne T.; Gumkowski,Michael J.; Lorenz,Douglas A.; Nightingale,James A. S.; Ruggeri,Roger B.; Shanker,Ravi M., Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors.
  145. Babcock, Walter C.; Curatolo, William J.; Friesen, Dwayne T.; Ketner, Rodney J.; Lo, Julian B.; Nightingale, James A. S.; Shanker, Ravi M.; West, James B., Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers.
  146. Friesen, Dwayne T.; Gumkowski, Michael J.; Ketner, Rodney James; Lorenz, Douglas A.; Nightingale, James A. S.; Shanker, Ravi M.; West, James B., Pharmaceutical compositions of dispersions of drug and neutral polymers.
  147. Crew, Marshall; Friesen, Dwayne T.; Ketner, Rodney J.; Shanker, Ravi M.; West, James B., Pharmaceutical compositions of drugs and neutralized acidic polymers.
  148. Crew, Marshall; Friesen, Dwayne T.; Ketner, Rodney J.; Shanker, Ravi M.; West, James B., Pharmaceutical compositions of drugs and neutralized acidic polymers.
  149. Babcock, Walter C.; Caldwell, William B.; Crew, Marshall D.; Friesen, Dwayne T.; Shanker, Ravi M.; Smithey, Daniel T., Pharmaceutical compositions of semi-ordered drugs and polymers.
  150. Babcock, Walter C.; Caldwell, William B.; Crew, Marshall D.; Friesen, Dwayne T.; Shanker, Ravi M.; Smithey, Daniel T., Pharmaceutical compositions of semi-ordered drugs and polymers.
  151. Curatolo, William J.; Shanker, Ravi M.; Babcock, Walter C.; Friesen, Dwayne T.; Nightingale, James A. S.; Lorenz, Douglas A., Pharmaceutical compositions providing enhanced drug concentrations.
  152. Curatolo, William J.; Shanker, Ravi M.; Babcock, Walter C.; Friesen, Dwayne T.; Nightingale, James A. S.; Lorenz, Douglas A., Pharmaceutical compositions providing enhanced drug concentrations.
  153. Curatolo, William J.; Shanker, Ravi M.; Babcock, Walter C.; Friesen, Dwayne T.; Nightingale, James A. S.; Lorenz, Douglas A., Pharmaceutical compositions providing enhanced drug concentrations.
  154. Curatolo, William J.; Shanker, Ravi M.; Babcock, Walter C.; Friesen, Dwayne T.; Nightingale, James A. S.; Lorenz, Douglas A., Pharmaceutical compositions providing enhanced drug concentrations.
  155. Curatolo, William J.; Shanker, Ravi M.; Babcock, Walter C.; Friesen, Dwayne T.; Nightingale, James A. S.; Lorenz, Douglas A., Pharmaceutical compositions providing enhanced drug concentrations.
  156. Abu Shmeis, Rama Ali; Kowalski, James; Krill, Steven L.; Parthiban, Lakshman Jayanth; Wang, Zeren, Pharmaceutical formulation.
  157. Babcock, Walter C.; Friesen, Dwayne T.; Nightingale, James A. S.; Shanker, Ravi M., Pharmaceutical solid dispersions.
  158. Babcock, Walter C.; Friesen, Dwayne T.; Nightingale, James A. S.; Shanker, Ravi M., Pharmaceutical solid dispersions.
  159. Fleischer,Wolfgang; Reimer,Karen, Preparations for the application of anti-inflammatory agents.
  160. Fleischer,Wolfgang; Reimer,Karen, Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract.
  161. Fleischer,Wolfgang; Reimer,Karen, Preparations for the promotion of wound healing in the upper respiratory tract and/or ear.
  162. Ghebre Sellassie, Isaac; Terefe, Hibrenigus, Process for enhancing the solubility of poorly soluble drugs.
  163. Kessler, Thomas; Breitenbach, Jörg; Schmidt, Christoph; Degenhardt, Matthias; Rosenberg, Jörg; Krull, Harald, Process for producing a solid dispersion of an active ingredient.
  164. Kessler, Thomas; Breitenbach, Jörg; Schmidt, Christoph; Degenhardt, Matthias; Rosenberg, Jörg; Krull, Harald; Berndl, Gunther, Process for producing a solid dispersion of an active ingredient.
  165. Casebier, David S., Prodrugs of steroidal CYP17 inhibitors/antiandrogens.
  166. Tseng, Scheffer; He, Hua; Li, Wei, Purified amniotic membrane compositions and methods of use.
  167. Tseng, Scheffer; He, Hua; Li, Wei, Purified amniotic membrane compositions and methods of use.
  168. Tseng, Scheffer; He, Hua; Li, Wei, Purified amniotic membrane compositions and methods of use.
  169. Tseng, Scheffer; He, Hua; Li, Wei, Purified amniotic membrane compositions and methods of use.
  170. Chen, Wei; Loury, David J., Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors.
  171. Tuttle, Susan Bane; Dilek, Ozlem; Mukherjee, Kamalika, Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith.
  172. Hantke, Thomas; Rehbock, Bettina; Rosenberg, Jörg; Breitenbach, Jörg, Rate-controlled particles.
  173. Berndl, Gunther; Breitenbach, Jörg; Heger, Robert; Stadler, Michael; Wilke, Peter; Rosenberg, Jörg, Self-emulsifying active substance formulation and use of this formulation.
  174. Berndl, Gunther; Breitenbach, Jörg; Heger, Robert; Stadler, Michael; Wilke, Peter; Rosenberg, Jörg, Self-emulsifying active substance formulation and use of this formulation.
  175. Nomura, Yukihiro; Tsushima, Yuki; Ebisawa, Yutaka, Solid dispersion.
  176. Patel,Kamlesh H.; Pillai,Raviraj S., Solid dispersion compositions.
  177. Kigoshi Makoto,JPX ; Masada Tomoaki,JPX ; Ueno Yasuhiko,JPX ; Ishikawa Yasuhiro,JPX ; Hayakawa Eiji,JPX, Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer.
  178. Fort,James J.; Krill,Steven L.; Law,Devalina; Qiu,Yihong; Porter,William R.; Schmitt,Eric A., Solid dispersion pharamaceutical formulations.
  179. Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S., Solid pharmaceutical dispersions with enhanced bioavailability.
  180. Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S., Solid pharmaceutical dispersions with enhanced bioavailability.
  181. Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S., Solid pharmaceutical dispersions with enhanced bioavailability.
  182. Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S., Solid pharmaceutical dispersions with enhanced bioavailability.
  183. Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S., Solid pharmaceutical dispersions with enhanced bioavailability.
  184. Berndl, Gunther; Rosenberg, Joerg; Liepold, Bernd; Breitenbach, Joerg; Reinhold, Ulrich; Alani, Laman; Ghosh, Soumojeet, Solid pharmaceutical dosage form.
  185. Rosenberg, Jeorg; Reinhold, Ulrich; Liepold, Bernd; Berndl, Gunther; Breitenbach, Joerg; Alani, Laman; Ghosh, Soumojeet, Solid pharmaceutical dosage form.
  186. Rosenberg, Joerg; Reinhold, Ulrich; Liepold, Bernd; Berndl, Gunther; Breitenbach, Joerg; Alani, Laman; Ghosh, Soumojeet, Solid pharmaceutical dosage form.
  187. Rosenberg, Joerg; Reinhold, Ulrich; Liepold, Bernd; Berndl, Gunther; Breitenbach, Joerg; Alani, Laman; Ghosh, Soumojeet, Solid pharmaceutical dosage form.
  188. Rosenberg, Joerg; Reinhold, Ulrich; Liepold, Bernd; Berndl, Gunther; Breitenbach, Joerg; Alani, Laman; Ghosh, Soumojeet, Solid pharmaceutical dosage form.
  189. Rosenberg, Joerg; Reinhold, Ulrich; Liepold, Bernd; Berndl, Gunther; Breitenbach, Joerg; Alani, Laman; Ghosh, Soumojeet, Solid pharmaceutical dosage form.
  190. Rosenberg, Jöerg; Reinhold, Ulrich; Liepold, Bernd; Berndl, Gunther; Breitenbach, Jörg; Alani, Laman L.; Ghosh, Soumojeet, Solid pharmaceutical dosage formulation.
  191. Baruah, Anima; De, Dibyendu; Khanna, Ish Kumar; Pillarisetti, Sivaram; Maitra, Santanu; Alexander, Christopher W.; Sreenu, Jennepalli; Dager, Indu; Alikunju, Shanavas, Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors.
  192. Baruah, Anima; De, Dibyendu; Khanna, Ish Kumar; Pillarisetti, Sivaram; Maitra, Santanu; Alexander, Christopher W.; Sreenu, Jennepalli; Dager, Indu; Alikunju, Shanavas, Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors.
  193. Boruah, Anima; Alikunju, Shanavas, Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors.
  194. Song, Jiangao; McWherter, Charles A.; Ma, Fang; Andres, Mark; Ivanisevic, Igor; Albert, Ekaterina; Andres, Patricia, Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts.
  195. Song, Jiangao; McWherter, Charles A.; Ma, Fang; Andres, Mark; Ivanisevic, Igor; Albert, Ekaterina; Andres, Patricia, Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts.
  196. Song, Jiangao; McWherter, Charles A.; Ma, Fang; Andres, Mark; Ivanisevic, Igor; Albert, Ekaterina; Andres, Patricia, Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts.
  197. Heafield Joanne,GBX ; Knott Trevor John,GBX ; Leslie Stewart Thomas,GBX ; Malkowska Sandra Therese Antoinette,GBX ; Miller Ronald Brown,CHX ; Prater Derek Allan,GBX ; Smith Kevin John,GBX, Sustained release compositions and a method of preparing pharmaceutical compositions.
  198. Heafield Joanne,GB2 ; Knott Trevor John,GB2 ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Miller Ronald Brown,CHX ; Prater Derek Allan,GB2 ; Smith Kevin John,GB2, Sustained release compositions of morphine and a method of preparing pharmaceutical compositions.
  199. Huang, Yanbin; Sheikh-Ali, Bashir Musse; Kim, Jaeho, Temperature responsive delivery systems.
  200. Breitenbach, Jorg; Heger, Robert; Simon, Dirk; Liepold, Bernd, Test system for characterizing the compatibility of bioactive substances and polyvinylpyrrolidone.
  201. Brough, Chris; McGinity, James W.; Miller, Dave A.; DiNunzio, James C.; Williams, III, Robert O., Thermo-kinetic mixing for pharmaceutical applications.
  202. Brough, Chris; McGinity, James W.; Miller, Dave A.; Dinunzio, James C.; Williams, III, Robert O., Thermo-kinetic mixing for pharmaceutical applications.
  203. Antonio Moroni ; William Drefko, pH-dependent sustained release, drug-delivery composition.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로